CG Oncology, Inc. (NASDAQ:CGON) is one of the best healthcare stocks with the highest upside. On October 7, CG Oncology, Inc. (NASDAQ:CGON) was initiated with a Buy rating by Guggenheim analyst Brad Canino, who assigned the stock a $90 price target.
The firm told investors in a research note that it sees the company “rising to the top of quality oncology ideas.” It added that the non-muscle invasive bladder cancer market holds considerable pricing power and a number of patients, supporting the optimistic rating for CG Oncology, Inc..
Canino also cited CG Oncology, Inc.’s cretostimogene, which would enter FDA review in 2026, as a notable factor, highlighting its “best-in-class” efficacy and safety durability.
CG Oncology, Inc. is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for bladder cancer. Its product cretostimogene is initially in clinical development for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The company is making significant advancements across its pipeline to develop a potential backbone bladder-sparing therapy for NMIBC. With a strong tolerability profile and safety, cretostimogene has the potential to induce a durable, complete response in bladder cancer patients.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
